arrow
G

Gerard H. Koppelman

University of Groningen
H指数:88
被引数:3.1万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Maternal influences on infant gut microbiome and health

母体对婴儿肠道微生物群与健康的影响

Nature
IF48.5
2026-08-120
OAAI
Distinction between allergic rhinitis alone and allergic rhinitis plus asthma in MASK-air ® real-world studies; a ARIA-WAO task force review

MASK-air ®真实世界研究中单纯过敏性鼻炎与过敏性鼻炎合并哮喘的区分;一项ARIA-WAO工作组综述

2026-07-010
OAAI
Prenatal Smoking Exposures and Epigenome-Wide Methylation in Newborn Blood

孕期吸烟暴露与新生儿血液表观基因组范围的甲基化

2026-04-010
OAAI
The impact of environmental exposures on DNA methylation in the EXPANSE project

EXPANSE项目中环境暴露对DNA甲基化的影响

2025-12-190
OAAI
Road traffic noise exposure and blood DNA methylation at birth and in childhood: An epigenome-wide meta-analysis

道路交通噪声暴露与出生时及儿童期的血液DNA甲基化:一项表观基因组-wide荟萃分析

2025-12-020
OAAI
Predictors of Response to Biologics for Severe Asthma: A Systematic Review and Meta-Analysis

对重症哮喘生物制剂反应的预测因素:一项系统评价和Meta分析

2025-09-160
OAAI
Gene–Environment Interaction Affects Risk of Atopic Eczema: Population and In Vitro Studies

基因-环境交互作用影响特应性湿疹的风险:人群研究和体外研究

2025-06-040
OAAI
General population-based lung function trajectories over the life course: an accelerated cohort study

基于一般人群的肺功能生命历程轨迹:一项加速队列研究

2025-05-150
OA
Quantification of Ivacaftor, Tezacaftor, Elexacaftor, and Lumacaftor and their active metabolites in plasma using UHPLC-MS/MS: Doors open to the application of therapeutic drug monitoring in cystic fibrosis treatment

使用UHPLC-MS/MS对血浆中Ivacaftor、Tezacaftor、Elexacaftor和Lumacaftor及其活性代谢物进行定量:为囊性纤维化治疗中治疗药物监测的应用打开大门

2025-05-010
PRE
Introduction of Ivacaftor/Lumacaftor in Children With Cystic Fibrosis Homozygous for F508del in the Netherlands: A Nationwide Real-Life Study

荷兰国家真实世界研究:F508del纯合子囊性纤维化儿童中伊伐卡托/鲁马卡托的引入

2025-01-090
OAAI